Biome Acne combines three scientifically-validated probiotic strains specifically selected for their ability to address acne through the gut-skin axis. This targeted approach recognises that skin health is intimately connected to gut microbiome balance and systemic inflammation, offering a novel therapeutic pathway for managing acne from within.

Lactobacillus salivarius LS-03 serves as a powerful anti-inflammatory agent in this formulation, working to suppress IL-8 production - a key cytokine that drives the inflammatory cascade in acne lesion formation. This strain generates potent bacteriocins that directly inhibit Cutibacterium acnes (the primary bacterial contributor to acne) and Staphylococcus aureus, effectively limiting both bacterial overgrowth and the inflammatory activation that follows. By targeting these dual pathways, LS-03 helps reduce the bacterial burden on the skin while simultaneously calming the immune response that creates visible inflammation.

Bifidobacterium breve BR-03 contributes essential anti-inflammatory support by reducing key acne-related cytokines including IL-8 and TNF-α, which are central to the inflammatory processes that create red, swollen acne lesions. This strain works systemically to calm inflammatory signalling throughout the body while helping restore microbial balance in both the gut and skin microbiomes. BR-03 also exhibits antimicrobial activity against opportunistic bacteria that contribute to acne-associated dysbiosis, supporting a healthier overall bacterial environment.

Lacticaseibacillus casei LC-03 rounds out this synergistic combination by providing additional antimicrobial defence through the production of bacteriocins that directly inhibit C. acnes growth. This strain also downregulates IL-8 production, further dampening the inflammatory cascade that drives lesion formation. The combined antimicrobial and anti-inflammatory actions of LC-03 work alongside the other strains to create a comprehensive approach to acne management.

Clinical research demonstrates the effectiveness of this three-strain combination in real-world applications. In individuals with mild to moderate acne, 8 weeks of supplementation with BR-03, LC-03, and LS-03 resulted in a 38.89% reduction in acne lesion count, accompanied by significant decreases in sebum production. Importantly, microbiome analysis showed a marked decline in C. acnes populations and an increase in beneficial commensals such as Staphylococcus epidermidis, indicating effective rebalancing of the skin microbiome [19]. This research confirms that addressing acne through targeted probiotic intervention can produce meaningful clinical improvements while supporting long-term skin health through microbiome restoration.